Finally, intraperitoneal administration of recombinant human ACE2 (2 mg/kg−1/d−1) prevented Ang II-induced hypertension, renal oxidative stress and tubulointerstitial fibrosis in a mice model [50], suggesting ACE2 as a potential therapeutic treatment for cardiovascular and renal diseases. Here, ACE2 is linked to hypertensive disorder.